Delay in Publication of Results

Pharma C Investments PLC

30 June 2023

 

30 June 2023

Pharma C Investments PLC
("Pharma C" or the "Company")

Delay in Publication of Results

Pharma C Investments (AQSE: PCIL), an early-stage investor and venture builder in the medical cannabis industry with a particular focus on companies that provide ancillary products and services to the medicinal cannabis sectors, announces that it will not be able to publish its audited financial statements for the year ended 31 December 2022 by 30 June 2023, as required by the AQSE Growth Market Access Rulebook.

The Directors currently envisage that they will be in a position to publish the Company's results in early July and further announcements will be made in due course.

This announcement contains inside information for the purposes of Article 7 of the Regulation (EU) No 596/2014 on market abuse

The Directors of the Company accept responsibility for the contents of this announcement.

For further information please visit www.pharmacinvestments.com 

For additional information please contact:

Pharma C Investments

Gavin Sathianathan, Investment Strategy Director

[e-mail]

Novum Securities

(AQSE Corporate Adviser)

Tel: [phone]

David Coffman

 

END